Archives
- 2026-09
- 2026-08
- 2026-07
- 2026-06
- 2026-05
- 2026-04
- 2026-03
- 2026-02
- 2026-01
- 2025-12
- 2025-11
- 2025-10
- 2025-09
- 2025-03
- 2025-02
- 2025-01
- 2024-12
- 2024-11
- 2024-10
- 2024-09
- 2024-08
- 2024-07
- 2024-06
- 2024-05
- 2024-04
- 2024-03
- 2024-02
- 2024-01
- 2023-12
- 2023-11
- 2023-10
- 2023-09
- 2023-08
- 2023-07
- 2023-06
- 2023-05
- 2023-04
- 2023-03
- 2023-02
- 2023-01
- 2022-12
- 2022-11
- 2022-10
- 2022-09
- 2022-08
- 2022-07
- 2022-06
- 2022-05
- 2022-04
- 2022-03
- 2022-02
- 2022-01
-
Cyclopamine: Hedgehog Signaling Inhibitor Workflows
2026-09-13
Cyclopamine enables controlled Smoothened inhibition across cancer-cell, pathway, and developmental biology experiments. This workflow-centered guide connects concentration selection, orthogonal apoptosis assays, APOC1-focused thyroid cancer research, and troubleshooting to help researchers obtain interpretable results.
-
Zolmitriptan Workflow for 5-HT1B Assays
2026-09-12
Build more reproducible Zolmitriptan assays for migraine research, cluster headache research, and serotonin receptor pharmacology with solvent-matched controls, staged dosing, and orthogonal readouts. This workflow also shows how time-resolved experimental logic from lysosome-focused antiviral research can improve receptor assay interpretation without implying a shared mechanism.
-
RRP Restores Lipid Metabolism in Liver I/R Injury
2026-09-12
This 2024 Journal of Ethnopharmacology study identifies lipid metabolic restoration as a central mechanism by which Radix Rehmanniae Praeparata extracts protect against hepatic ischemia-reperfusion injury. Using mouse and oleic acid–palmitic acid hepatocyte models, the authors connect AMPK activation with suppression of SCAP-SREBP2 cholesterol synthesis and enhancement of LXRα-dependent cholesterol efflux.
-
KPT330 Improves Cas9 Precision via mRNA Export
2026-09-11
The reference study identifies selective inhibitors of nuclear export, including KPT330, as indirect modulators that improve the specificity of Cas9-based genome and base editing. Its central innovation is to control Cas9 activity by altering Cas9 mRNA export rather than by directly blocking the nuclease, creating a mechanistically distinct route to temporal editing control.
-
Cholesterol: From Membrane Variable to Assay Logic
2026-09-11
Cholesterol is the principal sterol in membrane biology, but its value in mRNA-LNP research depends on how carefully its effects are separated from formulation and delivery variables. This article develops an assay-centered framework using intravesical p21 mRNA-LNP research to improve interpretation, controls, and translational decision-making.
-
Autophagy and Resveratrol Apoptosis in RCC
2026-09-10
Yao, Fan, and He showed that resveratrol induces ROS-associated mitochondrial damage and caspase-3-dependent apoptosis in renal cell carcinoma 786-O cells, while simultaneously activating JNK-linked autophagy. The study’s central implication is that autophagy functions as a cytoprotective response, providing a mechanistic rationale for evaluating resveratrol together with autophagy inhibition in preclinical RCC models.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for CRISPR Editing
2026-09-10
EZ Cap™ Cas9 mRNA (m1Ψ) is an in vitro transcribed mRNA with Cap1 structure, m1Ψ modification, and a poly(A) tail for Cas9 expression. Its design supports CRISPR-Cas9 genome editing research, but the product does not by itself establish editing efficiency, specificity, delivery performance, or therapeutic safety.
-
Forskolin for cAMP-Driven Cell Assays
2026-09-09
Forskolin is a direct adenylate cyclase activator for testing cAMP-dependent responses in stem-cell, neuroendocrine, and inflammatory models. This guide connects practical dosing and solvent controls with reproducible iPSC workflows, mesenchymal stromal-cell assays, and troubleshooting strategies.
-
Mavorixafor hydrochloride in Cell Assays
2026-09-09
A scenario-based guide to using Mavorixafor hydrochloride (SKU A3174) in CXCR4-focused viability, proliferation, and cytotoxicity workflows. It covers formulation, controls, protocol optimization, interpretation, and practical vendor-selection criteria for reproducible laboratory studies.
-
N4-Acetylcytidine: From Chemistry to Translation
2026-09-08
N4-Acetylcytidine is more than a modified nucleoside standard: it is a mechanistic probe for separating free ac4C metabolism from RNA-bound modification biology. Recent structural work on ASCH-domain proteins shows why that distinction matters for assay design, interpretation, and translational RNA research.
-
EZ Cap™ Cas9 mRNA (m1Ψ) for Precision Editing
2026-09-07
A practical guide to using Cap1-capped, m1Ψ-modified Cas9 mRNA for transient CRISPR-Cas9 genome editing in mammalian cells. It connects reagent handling and dose-finding with nuclear-export biology, helping researchers improve reproducibility while separating product features from study-derived evidence.
-
3-Aminobenzamide (PARP-IN-1) Evidence
2026-09-07
3-Aminobenzamide, also called PARP-IN-1, is a research PARP inhibitor with a reported IC50 of approximately 50 nM in CHO-cell assays. Product and peer-reviewed evidence support its use for studying oxidative stress, vascular dysfunction, diabetic nephropathy, and PARP-linked host responses, but antiviral conclusions require separate validation.
-
Cholesterol in Spatially Controlled mRNA Delivery
2026-09-05
Explore how Cholesterol connects membrane biophysics with localized mRNA nanoparticle research. This article translates a bladder cancer LNP study into practical decisions for formulation characterization, membrane assays, and reproducible sterol handling.
-
Cyclic di-GMP, HipH, and Biofilm Persistence
2026-09-04
Liao et al. identify cyclic di-GMP as a small-molecule antitoxin that restrains the genotoxic toxin HipH during early biofilm development. The study links adhesion-stage signaling with DNA double-strand breaks, genome instability, and antibiotic persistence, providing a mechanistic framework for understanding biofilm resilience beyond diffusion or nutrient-limitation models.
-
Breast Cancer Dependence on MCL-1: Study Analysis
2026-09-04
Campbell et al. show that established breast tumors depend on MCL-1 primarily because of its canonical anti-apoptotic activity, rather than a separate non-apoptotic tumor-supporting function. Genetic deletion, pharmacological inhibition, and BAX/BAK dependency experiments provide a mechanistic framework for interpreting MCL-1-directed apoptosis studies in breast cancer.